Form 4: Verve Therapeutics Director Krishna Yeshwant Acquires Stock Options

Director Krishna Yeshwant acquired stock options in Verve Therapeutics, Inc. on June 26, 2024, under the company's 2021 Stock Incentive Plan.

Summary

• Krishna Yeshwant, a director of Verve Therapeutics, Inc., acquired stock options on June 26, 2024.
• The stock options, granting the right to buy 136,139 shares of common stock, were issued under the company's 2021 Stock Incentive Plan.
• The exercise price of the options is $5.02 per share.
• The options vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The expiration date for the options is June 25, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a stable and incentivized leadership structure. The sentiment is neutral to positive as it aligns director interests with shareholder value.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing them to work towards the company's success.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry.
• Companies like CRISPR Therapeutics and Beam Therapeutics also utilize stock options as part of their director compensation packages.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing continued service.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates